
Abiomed ABMD
Quarterly report 2023-Q2
added 05-23-2026
Abiomed General and Administrative Expenses 2011-2026 | ABMD
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Abiomed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 423 M | 334 M | 342 M | 322 M | 263 M | 218 M | 164 M | 126 M | 107 M | 84.2 M | 71.7 M | 62.3 M | 60.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 423 M | 60.8 M | 198 M |
Quarterly General and Administrative Expenses Abiomed
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 M | 118 M | - | 108 M | 103 M | 103 M | 108 M | 86.2 M | 79.2 M | 68.4 M | 86.2 M | 85.7 M | 86 M | 86.1 M | 85.7 M | 80.2 M | 78.9 M | 81.1 M | 80.2 M | 66.6 M | 60.1 M | 60.6 M | 66.6 M | 53.9 M | 53.1 M | 51 M | 53.9 M | 41.9 M | 39.8 M | - | 41.9 M | 119 M | 77.2 M | 37.3 M | 30.1 M | 30.1 M | 29.5 M | 31.6 M | 24.4 M | 24.4 M | 26.2 M | 28 M | 20.9 M | 20.9 M | 18.4 M | 21 M | 17.2 M | 17.2 M | 16.3 M | 18.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 16.3 M | 59.1 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
45.8 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.82 | 3.32 % | $ 335 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 8.06 | -2.54 % | $ 1.21 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
14.1 M | $ 4.31 | 0.23 % | $ 161 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.3 | 0.44 % | $ 50.7 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.04 | 2.97 % | $ 17.6 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.46 | 0.39 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 17.9 | -2.56 % | $ 420 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 10.83 | -1.72 % | $ 388 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
LENSAR
LNSR
|
45.2 M | $ 6.05 | -0.66 % | $ 72.3 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 75.42 | 2.15 % | $ 4.11 B | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.57 | 1.29 % | $ 63.9 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.67 | 1.38 % | $ 542 M | ||
|
Electromed
ELMD
|
39.3 M | $ 38.3 | 0.21 % | $ 324 M | ||
|
Myomo
MYO
|
14 M | $ 1.03 | -0.96 % | $ 43.1 M | ||
|
Butterfly Network
BFLY
|
39.2 M | $ 4.54 | 1.68 % | $ 1.12 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
554 M | $ 9.77 | -9.12 % | $ 387 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 85.1 | 0.34 % | $ 11.5 B | ||
|
Profound Medical Corp.
PROF
|
32.1 M | $ 6.77 | -0.88 % | $ 205 M | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 153.8 | -0.69 % | $ 10.8 B | ||
|
CONMED Corporation
CNMD
|
132 M | $ 36.06 | -3.14 % | $ 1.12 B | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.43 | 1.67 % | $ 6.74 M | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 41.99 | -4.22 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 90.14 | 0.96 % | $ 3.13 B | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 87.54 | 2.05 % | $ 51.2 B | ||
|
TransMedics Group
TMDX
|
185 M | $ 70.46 | 2.21 % | $ 2.4 B |